CURE.X
CURE.X

Biocure Technology Inc.

Statut
Actif
Émis et en Circulation20,206,974
Réservé pour Émission5,745,169
Devise
CSE Indice

À propos

Biocure Technology Inc.

Date d'inscription
10 mai 2010
Social
Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.